Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Psoriasis is an immune-mediated inflammatory skin disease characterized by the presence of erythematous and itchy plaques.
Psoriasis has a multifactorial pathogenesis, environmental and genetic factors contribute to its development.
Although interleukin-23 blockade has been shown to be highly effective in the treatment of psoriasis, relapses have occurred during therapy.
Our study aims to identify the cellular source of key cytokines involved in disease recurrence or persistence of at least one psoriatic lesion in patients affected by moderate- severe psoriasis treated with an anti-IL-23 biologic drug. The immune infiltrate of resistant or relapsed plaques during anti-IL-23 therapy will be analysed from skin biopsies.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Sperimental | Patients affected by moderate-severe psoriasis treated with anti IL-23 therapy for at least 6 months, according to label dose. |
| |
| No Sperimental | Patients affected by moderate-severe psoriasis that have not been already treated |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| skin biopsy | Procedure | punch biopsy (6 mm) of lesional psoriasis skin |
|
| Measure | Description | Time Frame |
|---|---|---|
| Identify the cellular source of key cytokines involved in disease recurrence or persistence of at least a psoriatic lesion | Through the integration of multiparametric immunofluorescence staining with RNA in situ hybridization technology, our study aims to identify the cellular source of key cytokines involved in disease recurrence or persistence of at least one lesion psoriatic lesion in patients with moderate-severe psoriasis, undergoing treatment with anti-IL-23. | through study completion, an average of 1 year |
| Measure | Description | Time Frame |
|---|---|---|
| immune biomarkers of sustained and prolonged response to treatment | Identification of possible immune biomarkers of sustained and prolonged response to anti-IL-23 biological therapy that will include the expression profile of biomarkers related to tissue immune memory. | through study completion, an average of 1 year |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Patients affected by moderate-severe psoriasis under anti IL-23 therapy
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Ketty Peris, Prof | Contact | +390630155284 | ketty.peris@policlinicogemelli.it |
| Name | Affiliation | Role |
|---|---|---|
| Ketty Peris, Prof | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Fondazione Policlinico Universitario A. Gemelli IRCCS, UOC Dermatologia | Recruiting | Rome | Lazio | 00168 | Italy |
Not provided
| ID | Term |
|---|---|
| D011565 | Psoriasis |
| ID | Term |
|---|---|
| D017444 | Skin Diseases, Papulosquamous |
| D012871 | Skin Diseases |
| D017437 | Skin and Connective Tissue Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided